The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 526.00
Bid: 526.00
Ask: 527.00
Change: -3.00 (-0.57%)
Spread: 1.00 (0.19%)
Open: 530.00
High: 530.00
Low: 524.00
Prev. Close: 529.00
POLR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AuM Update

12 Jan 2023 07:00

RNS Number : 4494M
Polar Capital Holdings PLC
12 January 2023
 

12 January 2023 Polar Capital Holdings plc

AuM Update

 

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, today provides its regular quarterly update of its unaudited statement of its Assets under Management ("AUM") and performance fees earned for the calendar year to 31 December 2022.

 

Group AUM (unaudited)

 

Polar Capital reports that as at 31 December 2022 its AuM were £18.5bn compared to £22.1bn at the end of March 2022, a decrease of 16% over the period. During the nine-month period, AuM decreased by net redemptions of £1.1bn, outflows from fund closures of £0.5bn and a £2bn decrease related to market movement and fund performance.

 

AuM movement in nine months to 31 December 2022

Open ended

funds

Investment

Trusts

Segregated mandates

Total

AuM at 1 April 2022

£16,590m

£4,378m

£1,153m

£22,121m

Net flows

£(1,035)m

£(85)m

£(29)m

£(1,149)m

Fund closures1

£(390)m

-

£(79)m

£(469)m

Market movement

and performance

£(1,233)m

£(766)m

£(33)m

£(2,032)m

Total AuM at

31 December 2022

£13,932m

£3,527m

£1,012 m

£18,471m

1 Return of funds to investors on closure of the Phaeacian mutual funds and related segregated mandate in Q1 and China Mercury and Melchior Global Equity funds in Q3.

 

Net performance fees (unaudited)

 

The table below sets out the position relating to net performance fee profits (after the deduction of staff interests) earned in the first nine months of the Group's financial year.

 

Performance fee profit

net of staff allocations

Nine months to

31 Dec 21

Year to

31 Mar 22

(year-end)

Nine months to

31 Dec 22*

Net performance fee profit

£4.3m

£4.1m

£1.9m*

 

\* The figures to December 2022 are reduced by what is expected to be approximately £1.5m of net deferment adjustments.

 

 

Gavin Rochussen, Chief Executive, commented:

 

"There has been continued demand and inflows into the Global Insurance, Healthcare Blue Chip, Smart Energy and Emerging Market Stars funds, with combined net inflows of £190m across these funds in the quarter.

 

"A combination of the continued risk off market sentiment leading into the end of the calendar year, net outflows, fund closures and fund performance meant that our AuM at the end of the nine-month period were £18.5bn compared to £18.8bn at the end of the previous quarter and £22.1bn at the end of March 2022. Total net outflows for the quarter were £304m.

 

"During the quarter, the rate of outflows from the open-ended Technology funds continued to decline, with £217m of outflows compared to £252m in the previous quarter and £380m in the first quarter of this financial year.

 

"While crystallised net performance fee profits for the period to 31 December 2022 were muted this year, long term performance remains strong with 64% of our Funds and 78% of AuM having outperformed their respective benchmarks since inception.

 

"We remain confident that with our diverse range of differentiated, active specialist fund strategies we are well-positioned to perform for our clients and shareholders over the long term."

 

 

 

For further information please contact:

 

Polar Capital

Gavin Rochussen (Chief Executive)

Samir Ayub (Finance Director)

 

+44 (0)20 7227 2700

Numis Securities Limited - Nomad and Joint Broker

Giles Rolls

Charles Farquhar

Stephen Westgate

 

+44 (0)20 7260 1000

 

 

Peel Hunt LLP - Joint Broker

Andrew Buchanan

 

+44 (0)20 3597 8680

 

Camarco

Ed Gascoigne-Pees

Jennifer Renwick

Phoebe Pugh

 

+44 (0)20 3757 4995

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDEAXFFFASDEFA
Date   Source Headline
26th Apr 202410:33 amRNSForm 8.3 - RENALYTIX PLC
17th Apr 20243:55 pmRNSDirector/PDMR Shareholding
12th Apr 20245:43 pmRNSHolding(s) in Company
11th Apr 20247:00 amRNSAuM Update
9th Apr 20244:01 pmRNSChange of Company Secretary
15th Mar 20243:02 pmRNSForm 8.3 - Renalytix PLC
15th Mar 202410:23 amRNSForm 8.3 - Renalytix PLC - Replacement
13th Mar 20246:14 pmRNSForm 8.3 - RENALYTIX PLC
7th Mar 20244:30 pmRNSHolding(s) in Company
6th Mar 20245:47 pmRNSForm 8.3 - DIRECT LINE INSURANCE GROUP PLC
6th Mar 20245:37 pmRNSForm 8.3 - RENALYTIX PLC
27th Feb 20242:19 pmRNSForm 8.3 - Wincanton PLC
7th Feb 20242:09 pmRNSDirector/PDMR Shareholding
1st Feb 20247:00 amRNSBlock listing Interim Review
25th Jan 20244:53 pmRNSForm 8.3 -Wincanton PLC
11th Jan 20247:00 amRNSAuM Update
10th Jan 20242:54 pmRNSHolding(s) in Company
10th Jan 20242:51 pmRNSHolding(s) in Company
20th Nov 20237:00 amRNSPolar Capital Holdings Unaudited interim results
9th Nov 20237:00 amRNSInvestor Presentation covering Interim Results
26th Oct 20237:00 amRNSNotice of Interim Results
12th Oct 20237:00 amRNSAuM Update
28th Sep 20235:36 pmRNSResult of AGM
18th Aug 20234:45 pmRNSDirector/PDMR Shareholding
1st Aug 202312:05 pmRNSBlock listing Interim Review
19th Jul 20234:34 pmRNSDirector/PDMR Shareholding
18th Jul 20234:30 pmRNSDirector/PDMR Shareholding
13th Jul 202311:01 amRNSDirector/PDMR Shareholding - Replacement
13th Jul 202310:48 amRNSDirector/PDMR Shareholding
13th Jul 202310:31 amRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSAuM Update
26th Jun 20233:34 pmRNSInvestor Presentation covering Full Year Results
26th Jun 20237:00 amRNSGroup Audited Results for year ended 31 March 2023
1st Jun 20237:00 amRNSTotal Voting Rights
25th May 202312:26 pmRNSIssue of Equity
10th May 20233:10 pmRNSDirector/PDMR Shareholding
21st Apr 20232:36 pmRNSHolding(s) in Company
14th Apr 20234:01 pmRNSDirector/PDMR Shareholding
13th Apr 20237:00 amRNSAuM Update
31st Mar 202312:23 pmRNSDirector/PDMR Shareholding
10th Mar 20233:17 pmRNSDirector/PDMR Shareholding
24th Feb 20235:18 pmRNSForm 8.3 - REDX Pharma PLC
16th Feb 20235:06 pmRNSDirector/PDMR Shareholding
7th Feb 202311:09 amRNSHolding(s) in Company
1st Feb 20237:00 amRNSBlock listing Interim Review
12th Jan 20237:00 amRNSAuM Update
30th Dec 20227:00 amRNSDirectorate Change
21st Nov 20227:00 amRNSUnaudited interim results
15th Nov 20227:00 amRNSInvestor Presentation covering Interim Results
24th Oct 20227:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.